Loading…
← CockpitCompetitor Analysis › 4967.T Kobayashi Pharmaceutical Co., Ltd.Open in the cockpit ↗

Kobayashi Pharmaceutical Co., Ltd.4967.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Household/Personal Care

Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.

≈ A niche OTC/consumer-health innovatorMomentum leader 90
Mkt cap
$3.25B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$9.18M
20-day average traded
Fwd P/E
48.7×
forward earnings
ROIC−WACC
-0.5 pp
WACC 5.0%
Hurdle
+16 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · JPY¥6,960
1D-0.9%
1W+0.4%
1M-3.8%
3M+25.0%
6M+19.6%
YTD+28.2%
1Y+33.3%
ATR %1.9%
52w lowhigh5.8% off high

What Kobayashi Pharmaceutical does

Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.

Earns by creating a household or health product for a niche no one has served, backing it with heavy advertising, and selling it through drugstores and supermarkets; repeat purchases then carry the brand. Sawaday air fresheners and Netsusama fever-cooling sheets are examples sold on the same shelves as its medicines.

In one line: A niche OTC/consumer-health innovator.

Products and services

  • OTC pharmaceuticals
  • Deodorizer/hygiene products
  • Health food supplements

Customers

  • Retail pharmacy/drugstore consumers

Where it sits in the supply chain

  • Consumer health
  • OTC pharma & niche health products
  • OTC medicines, deodorizers, health…

What could go right

  • Niche health/hygiene product demand

What could go wrong

  • Product recall/safety reputation risk
  • OTC regulatory scrutiny

Moat: narrow (brand, IP / patents). Track record of creating and branding new niche product categories ahead of competitors.

Headquarters: Osaka, Japan · Founded: 1886 · Employees: 3,731

Named competitors

Kobayashi Pharmaceutical at a glance

Size Kobayashi Pharmaceutical (4967.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $3.25B, the 343rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,960 on 18 Nov 2026.

Performance Over six months the shares gained 19.6%, against +0.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +4.3%); the operating margin is 6.1% (peer median 11.5%).

Valuation It trades at 48.7× forward earnings against a peer median of 19.9× (2nd most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points below its cost of capital (5.0% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20264967.T 120Peer median 103
Six months, rebased to 100: Kobayashi Pharmaceutical against the median of its 20 peers (local-currency closes).

Kobayashi Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥167B¥166B¥166B¥173B¥166B
Revenue growth—0%-5%+4%—
Gross profit¥82.7B¥79.4B¥82.8B¥93.2B¥89.7B
EBITDA¥19.8B¥23.6B¥32.9B¥31.8B¥31.9B
Net income¥4.58B¥3.66B¥10.1B¥20.3B¥20.0B
Free cash flown/a¥12.3B-¥14.8B¥5.60B¥17.2B
Capital expendituren/a¥14.0B¥26.6B¥13.6B¥16.2B
Total debt¥664M¥678M¥846M¥987M¥792M

Quarterly statements and history in the cockpit →

Kobayashi Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%1044ITP603605COTY05190049124527GILLETTE3008881928202367PGHH131826984922COLPAL1618904927CUPID4967.T6-month return →1-month return →
Up and to the right = strong over both horizons. Kobayashi Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%50×100×1044ITP603605COTY05190049124527GILLETTE1928202367PGHH13182698492269931618904967.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kobayashi Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%1044ITP603605COTY05190049124527GILLETTE2367PGHH13182698COLPAL16189049274967.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Kobayashi Pharmaceutical is the large dot.

Kobayashi Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4967.T vs 4527.T vs 4985.T vs 4912.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Kobayashi Pharmaceutical 4967.T$3.25B+20%+2%6%48.7×18.0%
Rohto Pharmaceutical 4527.T$3.87B+8%+7%12%16.5×-2.8%
Earth 4985.T$687M+7%+4%4%18.0×-1.6%
Lion 4912.T$3.85B+44%+6%8%24.3×0.9%

How Kobayashi Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kobayashi Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4967.TPeer medianRank in peer set
1-month return-3.8%+2.2%8th lowest of 21
6-month return+19.6%+0.3%6th highest of 21
Distance from 52-week high-5.8%-22.4%5th highest of 21
Revenue growth (TTM)+2.5%+4.3%10th lowest of 21
Operating margin6.1%11.5%5th lowest of 21
Forward P/E48.7×19.9×2nd most expensive of 20
Growth the price implies (Req g, 7 yrs)18.0%-0.4%3rd most demanding of 17
Growth delivered (Del g)+1.9%+10.2%5th lowest of 17
Hurdle (Req g minus delivered)+16.1 pp-3.3 pp2nd most demanding of 17
ROIC minus cost of capital-0.5 pp+5.3 pp4th lowest of 19
EV / EBITDA23.4×10.3×2nd most expensive of 17
Net debt / EBITDA-2.7×-0.8×5th least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kobayashi Pharmaceutical 4967.TJapan$3.25B+20%+2%6%48.7×18.0%+1.9%
Hengan Int'l 1044.HKHong Kong$3.27B-12%+2%11%9.1×-8.2%-0.1%
Interparfums ITP.PAFrance$3.49B+66%-4%18%26.9×15.6%+19.6%
Proya Cosmetics 603605.SSChina$2.87B-13%+2%13%10.9×-5.3%+23.1%
Coty COTYUnited States$3.71B+116%0%5%13.5×9.8%+4.6%
LG H&h 051900.KSSouth Korea$2.81B-14%-3%3%23.1×-4.6%-4.1%
Lion 4912.TJapan$3.85B+44%+6%8%24.3×0.9%+3.5%
Rohto Pharmaceutical 4527.TJapan$3.87B+8%+7%12%16.5×-2.8%+13.7%
Gillette India GILLETTE.NSIndia$2.53B-5%+8%28%37.1×14.9%+13.0%
Winner Medical 300888.SZChina$2.53B-6%+4%11%19.9×-5.2%-2.6%
Cosmax 192820.KSSouth Korea$2.51B+53%+25%8%18.8×n/an/a
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Mao Geping Cosmetics 1318.HKHong Kong$4.67B-8%+32%31%14.3×4.1%+41.1%
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Colgate-Palmolive (India) COLPAL.NSIndia$4.91B-23%+9%28%32.4×31.1%+4.5%
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
Cupid CUPID.NSIndia$5.22B+218%+125%33%n/an/an/a

Questions

Who are Kobayashi Pharmaceutical's main competitors?
Named competitors: Rohto Pharmaceutical (4527.T), S.T. Corporation (private or unlisted), Earth Corporation (4985.T), Taisho Pharmaceutical Holdings (private or unlisted), Lion Corporation (4912.T). The cockpit's measured peer set (industry) also includes Hengan Int'l (1044.HK), Interparfums (ITP.PA), Proya Cosmetics (603605.SS), Coty (COTY), LG H&h (051900.KS), Lion (4912.T).
Is Kobayashi Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 48.7× against a peer median of 19.9×, 2nd most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Kobayashi Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +19.6% against +0.3% for the median peer; over one year +33.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.